Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
607 studies found for:    Open Studies | "Stomach Diseases"
Show Display Options
Rank Status Study
21 Not yet recruiting Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer
Conditions: Gastric Cancer;   Gastroesophageal Junction Cancer
Interventions: Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Leucovorin;   Drug: Fluorouracil
22 Recruiting Institut Paoli Calmettes Cardia Cancer Database
Conditions: Stomach Neoplasms;   Cardia
Intervention: Other: Data collection
23 Not yet recruiting Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: Oxaliplatin plus S-1;   Drug: S-1 only
24 Recruiting Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
Conditions: Precision Cell Immunotherapy;   Chemotherapy;   Advanced Malignancies
Interventions: Drug: Chemotherapy;   Biological: Precision Cells
25 Recruiting Metronomic Chemotherapy in Advanced Gastric Cancer
Conditions: Metastatic Gastric Cancer;   Locally Advanced Gastric Cancer
Intervention: Drug: Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
26 Not yet recruiting Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
Conditions: Gastric Cancer;   Pancreas Cancer;   Bile Duct Cancer;   Gastroesophageal Cancer
Interventions: Behavioral: Early Palliative Care visit;   Other: EORTC-QLQ-C30 questionnaire;   Other: HADS score
27 Recruiting Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry
Conditions: Bladder Cancer;   Gastric Cancer
Interventions: Drug: OTL38;   Drug: ICG
28 Recruiting Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
Conditions: Gastric Cancer;   Dual or Multiple Tumor Tissue Paraffin Blocks
Interventions: Other: Dual or Multiple Paraffin Blocks;   Other: One Paraffin Blocks
29 Recruiting Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker
Condition: Gastric Cancer
Intervention: Procedure: Blood sample(10cc) collection
30 Recruiting Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
Condition: Stomach Neoplasms
Intervention: Procedure: Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections
31 Not yet recruiting The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I
Conditions: Lung Neoplasms;   Esophageal Neoplasms;   Stomach Neoplasms
Intervention: Other: Integrative Care
32 Not yet recruiting The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry
Condition: Gastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue Blocks
Intervention: Procedure: choose two tumor tissue paraffin blocks
33 Recruiting Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents
Conditions: OGD;   Gastric Ulcer Induced by Anti-platelet Agent;   Duodenal Ulcer Induced by Anti-platelet Agent
Interventions: Procedure: Second-look OGD;   Drug: Esomeprazole
34 Recruiting CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
Conditions: Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Pancreatic Carcinoma;   Triple-Negative Invasive Breast Carcinoma;   Malignant Glioma of Brain;   Colorectal Carcinoma;   Gastric Carcinoma
Intervention: Biological: anti-MUC1 CAR-pNK cells
35 Recruiting Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Conditions: Non-small Cell Lung Cancer;   Esophageal Cancer;   Gastric Cancer;   Pancreatic Cancer;   Hepatocellular Cancer;   Colorectal Cancer
Intervention: Other: Blood draws, urine and tissue asservation, bone marrow aspiration
36 Recruiting RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease
Conditions: Parkinson's Disease;   Gastroparesis;   Constipation
Interventions: Drug: RQ-00000010;   Drug: Placebo
37 Recruiting Comparisons Between Isoperistaltic and Antiperistaltic Gastrojejunostomy in Laparoscopic Distal Gastrectomy
Condition: Stomach Neoplasms
Interventions: Procedure: Isoperistaltic;   Procedure: Antiperistaltic
38 Not yet recruiting Metabolic Consequences of Gastrointestinal Surgery
Conditions: Gastrectomy;   Oesophagectomy;   Dumping Syndrome;   Hypoglycaemia
Interventions: Drug: Somatostatin;   Drug: Rifaximin
39 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
40 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years